Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Payables (2021 - 2025)

Krystal Biotech (KRYS) has disclosed Payables for 5 consecutive years, with $39.8 million as the latest value for Q4 2025.

  • Quarterly Payables rose 697.43% to $39.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $39.8 million through Dec 2025, up 697.43% year-over-year, with the annual reading at $39.8 million for FY2025, 697.43% up from the prior year.
  • Payables hit $39.8 million in Q4 2025 for Krystal Biotech, up from $31.7 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $50.8 million in Q1 2022 to a low of $1.8 million in Q1 2021.
  • Historically, Payables has averaged $19.9 million across 5 years, with a median of $19.3 million in 2022.
  • Biggest five-year swings in Payables: soared 2655.8% in 2022 and later crashed 82.27% in 2023.
  • Year by year, Payables stood at $16.3 million in 2021, then surged by 43.0% to $23.3 million in 2022, then plummeted by 82.27% to $4.1 million in 2023, then increased by 20.64% to $5.0 million in 2024, then soared by 697.43% to $39.8 million in 2025.
  • Business Quant data shows Payables for KRYS at $39.8 million in Q4 2025, $31.7 million in Q3 2025, and $26.5 million in Q2 2025.